Skip to main content

Cidara Therapeutics, Inc. (CDTX)

NASDAQ: CDTX · Delayed Price · USD
2.02
-0.11 (-5.16%)
Pre-market:Sep 20, 2021 8:53 AM EDT
2.13
0.04 (1.91%)
At close: Sep 17, 4:00 PM
Market Cap105.45M
Revenue (ttm)41.42M
Net Income (ttm)-48.74M
Shares Out48.68M
EPS (ttm)-1.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume199,097
Open2.07
Previous Close2.09
Day's Range2.05 - 2.13
52-Week Range1.46 - 3.28
Beta1.36
AnalystsBuy
Price Target6.17 (+189.7%)
Est. Earnings DateNov 4, 2021

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbrea...

IndustryBiotechnology
IPO DateApr 15, 2015
CEOJeffrey Stein
Employees79
Stock ExchangeNASDAQ
Ticker SymbolCDTX
Full Company Profile

Financial Performance

In 2020, CDTX's revenue was $12.07 million, a decrease of -42.30% compared to the previous year's $20.92 million. Losses were -$72.11 million, 75.5% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is 6.17, which is an increase of 189.67% from the latest price.

Price Target
$6.17
(189.67% upside)
Analyst Consensus: Buy

News

Cidara Therapeutics to Host Research and Development Day

Virtual event will highlight the broad potential of the Cloudbreak ® platform and the commercial potential for rezafungin

2 weeks ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Q2 Earnings and Revenues Surpass Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 166.67% and 415.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

1 month ago - GlobeNewsWire

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (IS...

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

1 month ago - GlobeNewsWire

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

2 months ago - GlobeNewsWire

Cidara Therapeutics Provides Leadership Update

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

2 months ago - GlobeNewsWire

Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and...

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

2 months ago - GlobeNewsWire

Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

3 months ago - GlobeNewsWire

Cidara to Present at Mycology 2021 Conference

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

3 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -129.41% and -83.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients ...

4 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patient...

5 months ago - GlobeNewsWire

Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies

Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.

Other symbols:JNJ
5 months ago - Zacks Investment Research

Why Acadia Pharma, Bio-path And Cidara Are Moving Today

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejec...

Other symbols:ACADBPTH
5 months ago - Benzinga

Cidara Therapeutics Stock Rises After Collaboration Agreement Janssen For Influenza Candidates

Cidara Therapeutics Inc (NASDAQ: CDTX) has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson (NYSE: JNJ), to develop a...

5 months ago - Benzinga

Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatme...

Collaboration includes exclusive worldwide rights to Cidara's CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding

5 months ago - GlobeNewsWire

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patient...

5 months ago - GlobeNewsWire

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

6 months ago - GlobeNewsWire

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

8 months ago - GlobeNewsWire

Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technica...

Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara's antifungal and antiviral programs Former head of commercial API manufacturing at...

9 months ago - GlobeNewsWire

Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

9 months ago - GlobeNewsWire

Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

9 months ago - GlobeNewsWire

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

10 months ago - GlobeNewsWire